Portugal – Antineoplastic and immunomodulating agents – 2023/0491-BRODALUMAB [210 MG/ 1.5 ML SOL INJ SERINGA]
Tender Description
BRODALUMAB [210 MG/ 1.5 ML SOL INJ SERINGA]
Unlock Full Tender Insight
Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.
It's free to get started. No credit card required.
